Bi-specific antibodies comprising anti-cd137 binding molecules
AssigneeLyvgen Biopharma Holdings Limited
InventorsJieyi WANG, Yi WU
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies binding to CD137 and bi-specific antibodies comprising such for targeting both CD137 and a second suitable antigen such as an immune checkpoint or modulator molecule. Examples include PD-1, PD-L1, GITR, CD40, or OX40. Also provided herein are therapeutic uses of such antibodies.
Claims48
A bi-specific antibody, comprising:
- (a) a first antibody moiety that binds human CD137, and
- (b) a second antibody moiety that binds an antigen selected from the group consisting of PD-1, PD-L1, GITR, CD40 and OX40.
The bi-specific antibody of claim 16, wherein the second antibody moiety is an anti-GITR antibody set forth in any one of claims 26-39.
An isolated antibody specific to human glucocorticoid-induced TNFR-related protein (GITR) (anti-GITR antibody), wherein the anti-GITR antibody comprises:
- (a) a heavy chain variable region (VH) comprising heavy chain complementary determining regions (CDRs) 1, 2, and 3, which are either identical to those of a reference antibody, or contain no more than five amino acid residue variations relative to the reference antibody, wherein the reference antibody is Lyv392 or Lyv396;
- and
- (b) a light chain variable region (VL), comprising light chain complementary determining regions (CDRs) 1, 2, and 3, which are either identical to those of the reference antibody or contain no more than five amino acid residue variations relative to the reference antibody.
A nucleic acid or a nucleic acid set, which collectively encodes an antibody of any one of the preceding claims.
Dependencies are inferred from the claim text.